Donepezil: cognitive function-improving drug for Alzheimer's disease

Donepezil, a cholinesterase inhibitor used to treat mild to moderate Alzheimer's disease, improves cognitive function by increasing acetylcholine levels in the brain. This article will start from the drug mechanism, clinical application, manufacturer and precautions, focusing on analyzing its efficacy and safety, with authoritative data support.

Drug mechanism and core functions

Donepezil improves memory and daily functioning in patients with Alzheimer's disease by reversibly inhibiting acetylcholinesterase and slowing neurotransmitter degradation. Clinical studies show that continuous use for 6 months can delay cognitive decline by about 20% (ADAS-cog scale). It should be noted that its efficacy varies among individuals and it cannot reverse the disease process.

Clinical applications and precautions

The recommended starting dose of this drug is 5 mg/day, which can be increased to 10 mg after one month. Common adverse reactions include nausea (17%), diarrhea (9%) and other gastrointestinal symptoms, which mostly occur during the dose adjustment period. Special groups such as patients with bradycardia should use it with caution, and attention should be paid to interactions with anticholinergic drugs when taking combined medications.

Manufacturer and dosage form information

Comprehensive assessment and medication recommendations

As a first-line drug for Alzheimer's disease, donepezil needs to be used regularly and long-term under the guidance of a neurologist. Coupling with cognitive training can enhance the efficacy. Liver and kidney function should be evaluated regularly during medication. It should be made clear that this drug is only a symptomatic treatment, and the patient's family should establish reasonable expectations.

Quote sources:
1. U.S. FDA Drug Insert (2022 revised edition)
2. "Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment in China" (Neurology Branch of the Chinese Medical Association)
3. Clinical trial data source: Birks JS et al. Cochrane Database Syst Rev. 2006(1)